Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...

In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...

AlloVir has entered into a definitive agreement for the acquisition of the complete outstanding shares of Kalaris ...

The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related ...

Purpose: To investigate the rate and risk factors for neovascular glaucoma (NVG) after vitrectomy in proliferative diabetic retinopathy (PDR). Methods: Five hundred and twelve patients (512 eyes ...

Opens in a new tab or window A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline ...

LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024- Appointed Jason Mitchell as chief ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...